All Orphans Must Get 10-Year Exclusivity, Says Top EU Court
This article was originally published in SRA
Executive Summary
In a judgment that upholds a central tenet of Europe's Orphan Drug Regulation, the Court of Justice of the EU has ruled that all orphan medicines are entitled to a full 10-year period of market exclusivity, even if they have been approved as "similar" to an existing orphan drug1.
You may also be interested in...
Off-Patent Industry Proposes Extensions To EU Market Protection Rather Than Data Exclusivity
Medicines for Europe proposed several alterations to the European Commission’s planned changes to exclusivity incentives at its recent Regulatory and Pharmacovigilance Conference in Brussels, most notably suggesting that the proposed extensions to data exclusivity should instead apply to market exclusivity.
Medicines For Europe Proposes Revised Remodulation To EU Exclusivity Proposals
Medicines for Europe proposed several alterations to the European Commission’s planted alterations to market exclusivity incentives at its recent Regulatory and Pharmacovigilance Conference in Brussels, most prominently that various proposed extensions to data exclusivity should instead be used to extend market exclusivity.
Changes To EU Orphan Similarity Concept Could Change Innovation Threshold For 10-Year Exclusivity
The European Commission has proposed changes to the existing criteria used for determining whether a new medicinal product is similar to an already authorized orphan drug and, therefore, whether it can be accepted for evaluation and granted 10-year market exclusivity.